WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that WuXi AppTec (WuXi), a leading supplier of R&D services to the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has purchased the Provantis Portal™ Remote Study Monitoring solution.

“WuXi's mission is to create a broad, integrated platform of R&D services that will allow anyone and any company to develop new medicines efficiently and cost effectively”

In 2009, WuXi selected Instem's integrated Provantis preclinical solution suite to automate study processes at their newly constructed 314,000 square-feet toxicology facility in Suzhou. The Provantis Portal, launched in 2012, now allows WuXi's toxicology clients to log into a secure Web site using any standard browser to view data from their on-going studies on-demand. This makes it easy for clients, particularly international organizations, to monitor their studies remotely while being able to more effectively communicate internally and with WuXi.

"WuXi's mission is to create a broad, integrated platform of R&D services that will allow anyone and any company to develop new medicines efficiently and cost effectively," said Stephen Mason, Vice President of Operations for Preclinical Services at WuXi. "The speed and quality of communications made possible by the Provantis Portal supports our commitment to better serve our customers globally through high-quality services."

Neil Donaldson, Vice President of Asian and European Operations at Instem, commented, "We are delighted that WuXi continues to take advantage of solutions from within our Study Workflow and Automation suite, and I'm encouraged to hear that their use of the Provantis Portal is bringing immediate value to them and their clients. It is also fantastic to see WuXi expand the number of users and modules of Provantis as they increase capacity at their Suzhou facility."

As the first western toxicology/pathology software supplier to enter the Chinese market, Instem officially deployed its first China-based system in one of the largest and most advanced vivariums during 2006. Acknowledging analyst projections that the People's Republic of China (PRC) is on pace to becoming the second largest pharmaceutical market in the world, Instem established a full-service office in Shanghai, recruited local staff and has localized the Provantis product suite into Mandarin Chinese. Instem is supporting international organizations and domestic laboratories exclusively serving the PRC using on-site systems as well as their SaaS delivery model from a professionally managed data center based in Shanghai.

Instem will be demonstrating its Provantis preclinical software suite and the Provantis Portal Remote Study Monitoring Solution at the 3^rd China Annual Meeting of Drug Toxicology, Suzhou, China, July 16-19^th.